Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection

Hiroki Taguchi^{1

2}, Taiga Otsuka^{3

4}, Mototsugu Shimokawa^{5

6}, Shiho Arima⁷, Shinichi Hashimoto⁷, Akio Ido⁷, Futa Koga⁸, Yujiro Ueda⁹, Junichi Nakazawa¹⁰, Azusa Komori¹¹, Satoshi Otsu¹¹, Masaru Fukahori¹², Akitaka Makiyama^{13

14}, Takuya Honda¹⁵, Taro Shibuki^{16

17}, Toshihiko Mizuta^{16

18}, Kenji Mitsugi¹⁹, Kenta Nio²⁰, Yasushi Ide²¹, Norio Ureshino^{22

23}, Tsuyoshi Shirakawa^{24

25}

Affiliations

¹ Department of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan.
² Department of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan.
³ Department of Medical Oncology, Saga Medical Center Koseikan, Saga, Japan; otsuka-t@umin.ac.jp.
⁴ Department of Internal Medicine, Minato Medical Clinic, Fukuoka, Japan.
⁵ Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
⁶ Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
⁷ Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
⁸ Department of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, Saga, Japan.
⁹ Department of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
¹⁰ Department of Medical Oncology, Kagoshima City Hospital, Kagoshima, Japan.
¹¹ Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
¹² Department of Internal Medicine, Division of Gastroenterology, Kurume University Hospital, Fukuoka, Japan.
¹³ Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.
¹⁴ Cancer Center, Gifu University Hospital, Gifu, Japan.
¹⁵ Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
¹⁶ Department of Internal Medicine, Imari Arita Kyoritsu Hospital, Saga, Japan.
¹⁷ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.
¹⁸ Department of Internal Medicine, Fujikawa Hospital, Saga, Japan.
¹⁹ Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan.
²⁰ Department of Medical Oncology, Sasebo Kyosai Hospital, Nagasaki, Japan.
²¹ Department of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
²² Department of Medical Oncology, Saga Medical Center Koseikan, Saga, Japan.
²³ Department of Medical Oncology, Kimitsu Chuo Hospital, Chiba, Japan.
²⁴ Department of Medical Oncology, Fukuoka Wajiro Hospital, Fukuoka, Japan.
²⁵ Karatsu Higashi-Matsuura Medical Association Center, Saga, Japan.

PMID: 34230153
DOI: 10.21873/anticanres.15145

Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection

Hiroki Taguchi et al. Anticancer Res. 2021 Jul.

. 2021 Jul;41(7):3573-3582.

doi: 10.21873/anticanres.15145.

Authors

Affiliations

¹ Department of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan.
² Department of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan.
³ Department of Medical Oncology, Saga Medical Center Koseikan, Saga, Japan; otsuka-t@umin.ac.jp.
⁴ Department of Internal Medicine, Minato Medical Clinic, Fukuoka, Japan.
⁵ Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
⁶ Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
⁷ Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
⁸ Department of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, Saga, Japan.
⁹ Department of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
¹⁰ Department of Medical Oncology, Kagoshima City Hospital, Kagoshima, Japan.
¹¹ Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
¹² Department of Internal Medicine, Division of Gastroenterology, Kurume University Hospital, Fukuoka, Japan.
¹³ Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.
¹⁴ Cancer Center, Gifu University Hospital, Gifu, Japan.
¹⁵ Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
¹⁶ Department of Internal Medicine, Imari Arita Kyoritsu Hospital, Saga, Japan.
¹⁷ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.
¹⁸ Department of Internal Medicine, Fujikawa Hospital, Saga, Japan.
¹⁹ Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan.
²⁰ Department of Medical Oncology, Sasebo Kyosai Hospital, Nagasaki, Japan.
²¹ Department of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
²² Department of Medical Oncology, Saga Medical Center Koseikan, Saga, Japan.
²³ Department of Medical Oncology, Kimitsu Chuo Hospital, Chiba, Japan.
²⁴ Department of Medical Oncology, Fukuoka Wajiro Hospital, Fukuoka, Japan.
²⁵ Karatsu Higashi-Matsuura Medical Association Center, Saga, Japan.

PMID: 34230153
DOI: 10.21873/anticanres.15145

Abstract

Background/aim: The aim of the study was to evaluate gemcitabine plus nanoparticle albumin-bound paclitaxel (GnP) and FOLFIRINOX for recurrent pancreatic cancer (rPC) after resection.

Patients and methods: Forty-four patients with rPC and 211 with de novo metastatic pancreatic cancer (mPC) who received GnP or FOLFIRINOX as first-line chemotherapy were retrospectively analyzed.

Results: On crude analysis, the median overall survival (OS) was significantly longer in the rPC group than in the mPC group (14.0 vs. 10.6 months, respectively; p=0.02). However, the difference was not significant on adjusted analysis using the Cox proportional hazards model (adjusted p=0.90). Patients receiving FOLFIRINOX (n=10) and GnP (n=34) in the rPC group had comparable OS (medians, 12.2 vs. 14.4 months, respectively; p=0.82) even after adjusting for covariates using the Cox model (adjusted p=0.18).

Conclusion: The outcomes of patients in the rPC and mPC groups were comparable following chemotherapy. Both FOLFIRINOX and GnP may be reasonable options for treating rPC.

Keywords: FOLFIRINOX (FFX); gemcitabine plus nanoparticle albumin–bound paclitaxel (GnP); recurrent pancreatic cancer after resection.

PubMed Disclaimer

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection

Affiliations

Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection

Authors

Affiliations

Abstract

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical